Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study

NCT02820857 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT02820857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02820857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 2
Overall status
Completed
Start date
September 4, 2017
Completion date
August 24, 2024
Enrollment
153 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinomas